Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of a Therapy With Cladribine Following a Treatment With Anti CD20 Compounds in Relapsing Multiple Sclerosis Patients: a Pilot Study

NCT04640818 is registered in ClinicalTrials.gov with Claudio Gobbi as lead sponsor.

NCT NCT04640818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04640818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of a Therapy With Cladribine Following a Treatment With Anti CD20 Compounds in Relapsing Multiple Sclerosis Patients: a Pilot Study
Lead sponsor
Claudio Gobbi
Phase
Observational
Overall status
Unknown status
Start date
December 17, 2020
Completion date
October 31, 2022
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis